-
February 14, 2013
Acorda Therapeutics Inc.'s (ACOR) fourth quarter earnings (including share-based compensation charges but excluding ...
-
February 11, 2013
Acorda Therapeutics, Inc. (ACOR) recently announced that data from preclinical studies evaluating glial growth ...
-
January 25, 2013
Acorda Therapeutics, Inc. (ACOR) recently announced that it has been awarded a research contract worth $2.67 million ...
-
January 09, 2013
Alkermes plc (ALKS) recently reaffirmed its view for fiscal 2013 (ending March 31, 2013). The company continues to ...
-
January 08, 2013
Acorda Therapeutics, Inc. (ACOR) recently disclosed unaudited sales of Ampyra (dalfampridine) extended release ...
-
January 03, 2013
This morning, the market has been relatively quiet. The Nasdaq remains relatively unchanged; the S&P 500 is ...
-
December 27, 2012
Acorda Therapeutics, Inc. (ACOR) recently completed the acquisition of privately-held Neuronex, Inc. As per the ...
-
December 19, 2012
Celgene Corporation (CELG) recently collaborated with Sutro Biopharma for the development of novel antibody drug ...
-
December 03, 2012
After the morning's trading, the Nasdaq is up 0.2%, the S&P 500 has declined 0.1% and the Dow is trading down 0.2%. ...
-
November 16, 2012
We are reverting to a Neutral recommendation on Alkermes plc (ALKS) from Outperform as we believe that the stock is ...
-
November 02, 2012
Acorda Therapeutics Inc. (ACOR) reported third quarter earnings (including share-based compensation charges but ...
-
October 23, 2012
Acorda Therapeutics Inc. (ACOR) recently announced that its patent no. 5,540,938 has been granted a five year patent ...
-
October 18, 2012
We recently initiated coverage on commercial-stage biopharmaceutical company Acorda Therapeutics, Inc. (ACOR) with a ...
-
September 18, 2012
We are moving back to a Neutral recommendation on Alkermes plc (ALKS) as we believe the stock is fairly valued at ...
-
August 28, 2012
On a bad day for the market, the Nasdaq has slipped 0.1%, the S&P 500 is trading down 0.1% and the Dow has decreased ...
-
August 14, 2012
Acorda Therapeutics Inc. (ACOR) recently announced results from a post-marketing commitment study evaluating a 5 mg ...
-
August 13, 2012
The market is having a bad day so far. The Nasdaq has declined 0.3%; the S&P 500 is down 0.4%; and the Dow has ...
-
August 01, 2012
Acorda Therapeutics Inc. (ACOR) reported second quarter earnings (including share-based compensation charges but ...
-
June 14, 2012
Acorda Therapeutics, Inc. (ACOR) recently announced the enrollment of the first patient in a proof-of-concept study ...
-
July 28, 2010
The Sanofi/Genzyme combination isn't the only biotech M&A activity on the radar.
